GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

bevacizumab   Click here for help

GtoPdb Ligand ID: 6771

Synonyms: Avastin® | rhuMAb-VEGF
Approved drug
bevacizumab is an approved drug (FDA (2004), EMA (2005))
Compound class: Antibody
Comment: Vascular endothelial growth factor A inhibitor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars: Amgen's bevacizumab-awwb (Mvasi®) was the first bevacizumab biosimilar to be FDA approved. This and others are listed in the table below.
NameTrade nameCompanyClinical PhaseIndications
bevacizumab-awwbMvasiAmgenApproved (FDA 2017)Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers.
bevacizumab-bvzr; PF-06439535ZirabevPfizerApproved (EMA & FDA 2019)Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney, cervical and breast cancers, plus recurrent glioblastoma (FDA).
SB8AybintioSamsung BioepisApproved (EMA 2020)Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
FKB238EquidacentCentus BiotherapeuticsApproved (EMA 2020)Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
bevacizumab; MYL-1402OAbevmyMylanApproved (EMA 2021)As per originator reference product.
bevacizumab-maly; BEVZ92-MB02Oyavas; AlymsysSTADA Arzneimittel/Amneal//mAbxience Approved (EMA 2021; FDA 2022)As per originator reference product: NOT adjuvant treatment of colon cancer
bevacizumabOnbevziSamsung Bioepis/BiogenApproved (EMA 2021)As per originator reference product
bevacizumab-adcd; CT-P16VegzelmaCelltrionApproved (EMA & FDA 2022)Approved to treat a range of advanced solid tumours in combination with other cancer drugs: Colorectal, breast, ovarian, fallopian tube, peritoneal, and uterine neoplasms, non-small cell lung cancer, and renal cell carcinoma
bevacizumab-tnjn; BAT1706 AvziviBio-Thera SolutionsApproved (FDA 2023, EMA 2024)Approved for use in the treatment of advanced lung and colorectal cancers
bevacizumab-vikg; ONS-5010LytenavaOutlook TherapeuticsApproved (EMA 2024)To treat neovascular (wet) age-related macular degeneration (nAMD)
bevacizumab-nwgdJobevneBiocon BiologicsApproved (FDA 2025)To treat advanced solid tumours
Classification Click here for help
Compound class Antibody
Approved drug? Yes. US FDA (2004)  |  EU EMA (2005)
WHO Essential Medicine WHO Essential Medicines List (EML) (23rd List, 2023). Access PDF version.
Click to view more information about the WHO Model Lists of Essential Medicines.
International Nonproprietary Names Click here for help
INN number INN
8017 bevacizumab
Synonyms Click here for help
Avastin® | rhuMAb-VEGF
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 24
Reactome Drug Reactome logo R-ALL-9679458
Reactome Reaction Reactome logo R-HSA-9679477
Other databases
GtoPdb PubChem SID 178103377
PubChem SID 178103377
Search PubMed clinical trials bevacizumab
Search PubMed titles bevacizumab
Search PubMed titles/abstracts bevacizumab
Wikipedia Bevacizumab